Improving Potency and Oral Bioavailability of Spinster Homolog 2 (Spns2) Inhibitor: A Structure-Activity Relationship Study

Dunnavant, Kyle Jacob2024-06-142024-06-142024-06-13vt_gsexam:40143https://hdl.handle.net/10919/119439ETDenIn CopyrightSphingosine-1-phosphateS1PSpns2transporter inhibitorlymphopeniaautoimmune diseasemultiple sclerosisulcerative colitisrenal fibrosisstructure-activity relationship studyImproving Potency and Oral Bioavailability of Spinster Homolog 2 (Spns2) Inhibitor: A Structure-Activity Relationship StudyDissertation